Grasselli S, Guerciolini R, Iadevaia V, Parise P, Gresele P, Nenci G G
Eur J Clin Pharmacol. 1987;32(2):207-10. doi: 10.1007/BF00542198.
We have studied the effect of indobufen, a cyclo-oxygenase blocking agent which has proved useful in patients with obstructive vascular disease, on red blood cell (RBC) filterability in vitro and in a pilot study ex vivo. The addition of indobufen in vitro to blood samples from 10 healthy volunteers did not significantly modify RBC deformability. We evaluated the ex vivo effect of indobufen (200 mg bd) in 14 patients with obstructive vascular disease. A significant improvement in RBC deformability was noted on the 5th, 14th, and 28th days of treatment, 2 h after the morning dose. Acetylsalicylic acid given to 6 similar patients had no effect suggesting that the positive haemorheological effect of indobufen is probably not linked to its cyclooxygenase blocking effect.
我们研究了吲哚布芬（一种已证实在阻塞性血管疾病患者中有效的环氧化酶阻断剂）对体外红细胞（RBC）过滤性以及一项离体初步研究中的影响。在体外向10名健康志愿者的血样中添加吲哚布芬，并未显著改变红细胞的可变形性。我们评估了吲哚布芬（200毫克，每日两次）对14名阻塞性血管疾病患者的离体影响。在治疗的第5天、第14天和第28天，早晨服药2小时后，观察到红细胞可变形性有显著改善。给予6名类似患者阿司匹林则无此效果，这表明吲哚布芬的积极血液流变学效应可能与其环氧化酶阻断作用无关。
